Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer

Published 10 Dec 2018

Stevenage, UK 10 December 2018 – Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer immunotherapies, today announces that it has appointed Dr Edwin Moses as Chairman of its Board of Directors. In addition, Dr Iraj Ali, currently Interim CEO, will become the permanent, full-time CEO of the Company.

Dr Moses was most recently CEO of Ablynx NV which was acquired by Sanofi for $4.8Bn in 2018. Edwin was CEO at Ablynx for more than 12 years and built it from a small R&D-focused organisation into a five hundred person commercial-ready business with a broad biologics pipeline including a wholly-owned product for a rare hematologic indication which was approved for use in Europe earlier this year. At Ablynx, Edwin led the Euronext Brussels listing, multiple successful private and public financings and the NASDAQ listing in 2017. He was also responsible for delivering a series of multi-billion-pound collaborations with major pharmaceutical companies.

Edwin has more than 25 years of Board level experience, both as CEO and Chairman, in more than 10 European life science companies. During his career to date, Edwin has raised more than €500M in equity and debt financing.

Dr Ali joined Achilles in January 2018 as Interim CEO, whilst also serving as a Partner of Syncona Ltd, Achilles’ founding investor. He joined Syncona in 2012 and was an investment partner and Board member of Nightstar Therapeutics, Blue Earth Diagnostics and Achilles Therapeutics. Dr Ali was previously with McKinsey & Company where he was involved in several major pharmaceutical launches across developed and emerging markets and was a co-founder of McKinsey’s US launch practice and leader of speciality launches in Europe.

Edwin Moses, Chairman of Achilles, said:
“I am delighted to become the Chairman of Achilles. The Company was founded by world-leading experts in the understanding of cancer evolution, bioinformatics and the development of cell-based immunotherapies. The potential of the technology is extremely exciting and together with a dynamic and talented management team and Board, I am very much looking forward to building an international immunotherapeutic company and realizing the full potential of the core science to develop products to improve the lives of patients and create value for investors.”

Iraj Ali, CEO of Achilles, added:
“We are on the brink of a revolution in cancer therapy driven by the convergence of bioinformatics and immuno-oncology, both of which are developing at a staggering pace. I have been involved with the development of the Achilles concept from its inception and I am delighted to become the CEO on a permanent basis and to welcome someone of Edwin’s calibre to be Chairman of our Board. Edwin brings exceptionally relevant experience to Achilles and together with his stewardship, I look forward to leading this business through its next phase of growth.”

Dr Martin Murphy, Chief Executive Officer of Syncona Investment Management Ltd commented:
“Iraj has played an integral role in the development of Syncona and has played an instrumental part in the foundation and subsequent progress of Achilles. We are delighted that he has chosen to transition from being the interim CEO to take on the role on a full-time basis. It serves to underscore our shared belief in Achilles, which is a truly innovative healthcare business with an opportunity to grow into a globally competitive commercial company.”


Achilles also recently announced the appointment of industry leader Michael F. Giordano, M.D., previously the Head of Immuno-Oncology and Oncology Development at Bristol-Myers Squibb responsible for approvals of Yervoy and Opdivo, as a non-executive director to its Board.

The Achilles Board composition is now as follows:

Edwin Moses, Chairman
Iraj Ali, Chief Executive Officer
Martin Murphy, Non-Executive Director
Elisa Petris, Observer
Professor Karl Peggs, Founder Director
Ian Walker, Non-Executive Director
Michael F. Giordano, Non-Executive Director


Further information:

Achilles Therapeutics
Dr Iraj Ali – Chief Executive Officer
+44 (0)1438 906 906
media@achillestx.com

JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com

Consilium Strategic Communications
Mary-Jane Elliot, Sukaina Virji, Melissa Gardiner
Tel: +44 (0) 203 709 5000
Email: achillestx@consilium-comms.com


Notes for Editors:

About Achilles Therapeutics
Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with proprietary bioinformatics technology, to identify clonal neoantigens specific to that patient and enable the development of personalised therapies.


Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, reduces the risk that new mutations can induce immune evasion and therapeutic resistance, and allows individualised treatments to target and destroy tumours without harming healthy tissues. Achilles was founded by lead Investor Syncona Ltd and its shareholders include the CRT Pioneer Fund, UCL Technology Fund, Cancer Research Technology, with the support of UCL Business (UCLB) and the Francis Crick Institute. For further information please visit the Company’s website at: www.achillestx.com

Syncona Limited Disclaimer

Please read the below disclaimer carefully. You will be asked to accept these terms and conditions before proceeding.

The information on this website is directed only at persons who are shareholders in Syncona Limited (the “Company”) and is provided for their exclusive use and benefit.

Users of this website are responsible for observing all applicable laws and regulations in their relevant jurisdictions before proceeding to access the information contained herein. By proceeding to access the information, users are deemed to be representing and warranting that the applicable laws and regulations of their relevant jurisdiction allow them to do so. No information, materials or opinions contained on this website (“Materials”) constitute or would be deemed to constitute a recommendation or invitation in any jurisdiction to invest or otherwise deal in the shares of the Company (the “Shares”).

The website that you are seeking to access does not constitute an offer to buy or sell the securities mentioned in the website in any jurisdiction or jurisdictions in which such offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In particular, the securities mentioned in the website have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or exemption from registration under the Securities Act and other securities laws. There will be no public offer of these securities in the United States. Offers and sales of these securities, and distribution of the related information, may also be subject to restrictions in other jurisdictions.

The website that you are seeking to access is not directed at and may not be viewed by or distributed to persons:

  • in the United States or who are U.S persons (as defined in Rule 902 under the Securities Act);

or

  • located in a jurisdiction where it is not lawful to access the materials.

The Materials are provided on an “as is” and “as available basis” and do not purport to be full or complete. The Company and its affiliates believe that the source of the Materials is reliable however they cannot and do not guarantee, either expressly or implicitly, and accept no liability for, the accuracy, validity, timeliness, merchantability or completeness of any information or data (whether prepared by the Company, its affiliates or by any third party) for any particular purpose or use or that the information or data will be free from error. The Company and its affiliates do not undertake any responsibility for any reliance which is placed by any person on any statements or opinions which are expressed herein. Neither the Company, nor any of its affiliates, directors, officers or employees will be liable or have any responsibility of any kind for any loss or damage that any person may incur resulting from the use of this information.Nothing contained in this website constitutes financial, investment, legal, tax or other advice and is not to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision.

The Materials on this website are provided for your personal use and informational purposes only and are subject to change without notice. The Company has the right to suspend or withdraw the provision of all or any of the website of the Materials without prior notice at any time.

The value of investments mentioned in this site, and the income from them may go down as well as up and investors may not get back the amount invested. Information on past performance, where given, is not a guide to future performance. Changes in rates of exchange between currencies may cause the value of investments to decrease or increase.
The Company is a registered closed-ended collective investment scheme registered pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 1987, as amended (the ‘‘POI Law’’) and the Registered Collective Investment Scheme Rules 2008 (the ‘‘CIS Rules’’) issued by the Guernsey Financial Services Commission (the ‘‘GFSC’’). Neither the GFSC nor the States of Guernsey Policy Council take any responsibility for the financial soundness of the Company or for the correctness of any of the statements made or opinions expressed with regard to it.

Copyright

Copyright of all images and text in this website is owned by or licensed to the Company or one of its affiliates unless otherwise noted. You may imprint, copy, download or temporarily store extracts from this website for your personal information and use. Any other use is prohibited unless you first request and obtain the prior written consent of the Company. You may not alter or otherwise make any changes to any material that you print or download from this website, including, without limitation, removing any identifying marks or legends from such material. In particular, you may not copy or use any part of this website on any other website, or link any other website to this website, without the prior written permission of the Company. You may not use the website for any purpose which is unlawful, abusive, libellous, obscene or threatening.

No Warranty

The Materials contained in this website are provided without any warranty of any kind, either expressed or implied, to the fullest extent permissible pursuant to applicable law. Neither the Company nor its affiliates assume any responsibility for the uninterrupted availability of this website or warrant that it will be error-free, that defects will be corrected, or that this website or the servers that make it available will be free of viruses or other harmful components.

Liability Waiver

You agree that under no circumstances, including, but not limited to, negligence, shall the Company or any of its affiliates be liable for any special or consequential damages that result from the access or use of, or the inability to access or use, the Materials on this website. This does not exclude or restrict any duty or liability that the Company has to its customers under the regulatory system in the United Kingdom or Guernsey.

Privacy Policy

This policy sets out what the Company and its affiliates do with any personal information collected from this website.

Any personal information collected from this website will be processed in accordance with relevant data protection laws.

You may use the public areas of this website without providing the Company or its affiliates with any personal information and the Company and its affiliates do not monitor or collect any personal information through your access to the public areas of this website. The Company and its affiliates do not use cookies to collect information but may gather other anonymous information to assist in improving the services.

If you chose to provide the Company and its affiliates with personal information, this information will only be used for the purposes of the service that you have requested. The Company and its affiliates will not sell or transfer any personal information to third parties without your permission, other than as required by law.

The Company and its affiliates are not responsible for the content or privacy policies of websites to which this website may link.

The Company and its affiliates are committed to protecting your personal information but in the event that the system is infiltrated by unauthorised third parties the Company and its affiliates will not be liable for any resulting misuse of personal information.

Linked Sites

The Company has not reviewed any website linked to this website and is not responsible for the contents of off-site pages or any other websites linked or linking to this website. If you follow any links from this website you do so at your own risk.

Links to this website may not be established without the prior written consent of the Company.

Governing Law

The terms and conditions of this legal notice shall be governed by and construed in accordance with the laws of Guernsey. Users of this website agree that any dispute or action arising out of or relating to these terms or any user’s use of this website shall be commenced only in the courts located in Guernsey, and users of this website hereby consent and submit to the exclusive jurisdiction of such courts for the purposes of any such dispute or action.

By accessing Materials on this website you agree to be bound by the foregoing limitations.